Summary Human topoisomerase II enzymes are targets for a number of widely used anticancer agents. We have analysed a lung adenocarcinoma cell line CALU3, which has co-amplified topoisomerase IIax and ERBB2 sequences, for the structure of the amplicon and for expression of both topoisomerase Ila and P. The al., 1989; Woessner et al., 1991) . Recent studies have also indicated that the alpha and beta enzymes are sublocalised within the nucleus to the nucleoplasm and nucleoli respectively (Negri et al., 1992) .
chromosome 17q amplified in CALU3 also includes the retinoic acid receptor a locus and is therefore similar to the amplicon observed in breast cancers carrying amplified topoisomerase IIa and retinoic acid receptor sequences. The use of fluorescence in situ hybridisation localises the amplified topoisomerase Ila sequences to a cluster on one chromosome with single copies localised to others. CALU3 expresses high levels of topoisomerase Ila as determined by Western blot, immunofluorescence and enzyme activity. The enzyme activity extracted from CALU3 is sensitive to inhibition by the topoisomerase II poison etoposide.
Topoisomerase Ip expression was observed in three lung cancer cell lines including CALU3 and was confined to the nucleoli. Thus, the CALU3 cell line is an ideal model to study the amplification and expression of topoisomerase Ila in adenocarcinomas.
Topoisomerase II enzymes localised in the nucleus catalyse the breakage and rejoining of DNA (Takano et al., 1992) . The enzyme cuts a gate in the DNA through which a second molecule of DNA can pass. This DNA manipulation is vital to a number of cellular processes such as chromosome con- densation, replication and segregation as well as gene transcription and topoisomerase II activity is associated with all these processes (Anderson & Roberge, 1992) .
Topoisomerase II activity in human cells can be attributed to the expression of two distinct genes. Topoisomerase II alpha is localised to chromosome 17q bands [21] [22] (TsaiPflugfelder et al., 1988) whereas topoisomerase II beta is localised to chromosome 3p24 Jenkins et al., 1992) . Both genes are functional but their products differ in sequence and biochemical activity (Jenkins et al., 1992; Drake et al., 1989) . Expression of the topoisomerase II alpha gene is cell cycle regulated in contrast to the relatively constant expression of the beta gene product Woessner et al., 1991) . Recent studies have also indicated that the alpha and beta enzymes are sublocalised within the nucleus to the nucleoplasm and nucleoli respectively (Negri et al., 1992) .
Interest in topoisomerase II is due both to its essential catalytic activity in normal cells and that it is a key target for a group of anticancer agents including etoposide, doxorubicin and mAMSA (Takano et al., 1992; Liu, 1989) . Topoisomerase II interactive drugs interfere with the normal catalytic cycle of the enzyme resulting in cell death. The quantity of topoisomerase II within a cell will determine its sensitivity to topoisomerase inhibitors with high levels conferring sensitivity to the cytotoxic effects of the drugs (Takano et al., 1992) . Indeed, one cell line selected for sensitivity to doxorubicin has increased expression of topoisomerase II compared to its parental line (Davies et al., 1988) . In addition, yeast cells which over express topoisomerase II encoded by a plasmid are hypersensitive to topoisomerase II inhibitors (Nitiss et al., 1992) . In contrast, cell lines selected for resistance to the cytotoxic actions of topoisomerase inhibitors express low levels of topoisomerase or produce a mutated protein with altered catalytic activity (Takano et al., 1992) . Due to the clinical use of topoisomerase II inhibitors (Muggia & Gill, 1991 ) the levels of expression in tumours may be important in determining the success of the treatment. Molecular changes at topoisomerase loci which result in altered expression are therefore important and recently it has been shown that the topoisomerase II alpha gene is co-amplified along with ERBB2 in a subset of breast adenocarcinomas (Keith et al., 1993) .
We have previously shown that the lung adenocarcinoma cell line CALU3, has co-amplification of ERBB2 and topoisomerase Ilcc, (Keith et al., 1992) . This cell line therefore provides a model to examine the role of topoisomerase Ila amplification and expression in drug sensitivity. We have now investigated the expression, localisation and enzymatic activity of both topoisomerase Ila and P in CALU3 and further characterised the amplicon containing the topoisomerase Ila gene. We show here that the amplified topoisomerase II alpha gene in CALU3 is expressed at a high level and that enzyme activity is inhibited by a topoisomerase II interactive drug. Immunofluorescence studies using antibodies against topoisomerase II alpha and beta show the alpha product to be expressed heterogeneously within the cell population. In contrast, the beta isoform is expressed in all cells and localised to the nucleolus. In addition, we show by fluorescence in situ hybridisation (FISH) (Merry et al., 1987) . Confirmation of the sensitivity of CALU3 to topoisomerase II inhibitory drugs was determined by a tetrazolium dye based microtitration assay as described previously (Plumb et al., 1989) .
Topoisomerase II alpha probe and probe labelling The topoisomerase II alpha probe used for in situ hybridisation was a 35 kilobase cosmid (Hochhauser et al., 1992) kindly provided by Dr Ian Hickson, (ICRF, Oxford). Cosmid DNA was labelled with digoxigenin-ll-dUTP by nick translation according to the manufacturer's instructions, (Boehringer Mannheim). Labelled cosmid was precipitated in the presence of a 50-fold excess of human COTI DNA and resuspended in hybridisation buffer consisting of 50% formamide, 2 x SSC (1 x SSC is 0.15 M NaCl, 0.015 M sodium citrate pH 7), 500 fg ml-' salmon sperm DNA, 5% dextran sulphate, at a concentration of 2 ng LI-'.
In situ hybridisation (Pinkel et al., 1986 , Nederlof et al., 1992 Metaphase spreads were fixed in 3: 1 methanol, acetic acid for 1 h and then treated with RNAse (1I00 tg ml-') for 1 h. Slides were then fixed in 1% paraformaldehyde in PBS and dehydrated. Chromosomes were denatured prior to hybridisation in 70% formamide/2 x SSC at 70°C for 2 min and dehydrated. Probe was denatured at 70°C for 5 min and allowed to reanneal at 37°C for 1 h. Ten microlitres of probe was applied to denatured chromosomes and hybridisation was carried out under a sealed coverslip overnight in a humidified chamber.
Probe detection After hybridisation slides were washed twice in 50% formamide, 1 x SSC, 42°C, 10 min, followed by two washes in 2 x SSC 42°C, 10 min each. Prior to immunocytochemical detection, slides were incubated with Boehringer Mannheim blocking buffer, (0.5% blocking reagent in 0.1 M maleic acid, 0.15 M NaCl pH 7.5, 0.05% Tween 20), for 30 min at 37°C. The first antibody was anti-digoxigenin raised in sheep (Boehringer Mannheim), 1 pig ml-', in the above buffer, 37°C, 1 h.
Slides were washed for 20 min in 0.1 M maleic acid, 0.15 M NaCl, 0.05% Tween 20, pH 7.5. The second antibody, FITC-conjugated donkey anti-sheep (Jackson ImmunoResearch), diluted in the above blocking buffer at 3 lig ml1 l was applied to slides for 30 min, 37°C. Slides were then washed for 30 min, counterstained with propidium iodide (0.4 yg ml-') and mounted in anti-fade medium (Vectashield, Vector Labs). Fluorescence was analysed on a Bio-Rad MRC-600 laser scanning confocal microscope equipped with a krypton/ argon ion laser using 488/568 nm line excitation and dual channel 522 nm and 585 nm emission filters.
Immunofluorescence Cells were cultured on multi-chamber slides at low cell density, rinsed in PBS and fixed in acetone for I min at room temperature. Slides were blocked in 3% BSA in PBS, 0.05% Tween 20 for 10 min prior to the addition of antibodies. Polyclonal antiserum against topoisomerase II alpha was obtained from TopoGen (Columbus Ohio), the monoclonal antibody to topoisomerase II beta was kindly provided by Dr G.C.B. Astaldi Ricotti (Negri et al., 1992 (Keith et al., 1993) . Densitometry was performed using a Molecular Dynamics laser scanning densitometer.
Southern blot analysis Genomic DNA was isolated from cell lines as previously described (Keith et al., 1992) , and digested with restriction enzymes according to the manufacturer's directories. Hybridisations were carried out as described previously (Keith et al., 1992) . The probe SPI was used to detect topoisomerase IIa sequences (Chung et al., 1989) , pHPKC-alpha 7 to detect PKCcx (Parker et al., 1986) , p63 to detect RARx and pHJi was used as a control for DNA loading (Keith et al., 1992 [21] [22] (Tsai-Pflugfelder et al., 1988; Mattei et al., 1988) . The PKCa locus has been mapped to chromosome 17q 22-24, (Parker et al., 1986) . Figure 1 shows (Keith et al., 1992) were included in the analysis. Figure 3 shows (Negri et al., 1992) and the data presented in Figure 4 confirms this. All three lines express the beta isozyme and it is expressed in every cell in the population. Immunocytochemistry is only semi-quantitative and due to the intense localised fluorescence pattern obtained when analysing expression of the beta protein, differences in expression levels between the three lines is difficult to assess. Figure 4e shows that using the polyclonal antiserum against the alpha protein, low levels of fluorescence can be detected in the nucleoli. Whether this represents a weak cross-reactivity of this antiserum with the beta protein or co-localisation of the alpha enzyme is not known.
Biochemical analysis of topoisomerase II activity In order to determine whether the high levels of topoisomerase II alpha protein observed in CALU3 has enzyme activity, decatenation assays were carried out. Topoisomerase II activity can be measured due to its ability to monomerise covalently linked kinetoplast DNA circles. Decatenation of kinetoplast DNA requires both the DNA breakage and strand passage activities of topoisomerase II. The decatenation assay does not however distinguish between the alpha and beta isoforms. Figure 5 shows that CALU3 has at least eight-fold more topoisomerase II activity than the other two Figure 5 are the same as those used for the Western analysis of topoisomerase II alpha expression shown in Figure 3 . The results of both analyses are in agreement with each other and show CALU3 to express high levels of topoisomerase II. Western blot analysis of the extracts used in the biochemical analysis for beta expression detected degraded beta protein of 150 kD (data not shown). The 150 kD breakdown product of the beta enzyme has been observed previously and shown to be active in the biochemical assays (Negri et al., 1992) . Thus, some of the topoisomerase II activity detected may be due to the Ji isoform.
The topoisomerase II activity in protein extracts from CALU3 is largely due to alpha enzyme expression (Figures 3,  4 and 5). The alpha gene is amplified in CALU3 (Figures 1  and 2) and so it is possible that it might contain genetic alterations rendering its protein insensitive to inhibition by topoisomerase II interactive drugs (Takano et al., 1992) . We therefore examined the ability of the topoisomerase II interactive drug etoposide to inhibit topoisomerase II activity in decatenation assays. Figure 6 shows that etoposide can inhibit topoisomerase II activity in extracts from all three cell lines, including CALU3. Due to the higher levels of topoisomerase II activity in CALU3, only 1.25 jg of extract was used per reaction in comparison to 2.5 jig for L-DAN and SK-MES.
Discussion
The adenocarcinoma cell line CALU3 has the co-amplification of topoisomerase II alpha and ERBB2 sequences characteristic of a subset of breast adenocarcinomas (Keith et al., 1992 (Keith et al., , 1993 (Figures 3 and 4) . Two distinct antibodies were used to examine alpha expression by Western and immunofluorescence therefore confirming by independent methods that the isoform detected is indeed the alpha product. Neither of the other two cell lines tested had such high levels of alpha expression (Figures 3 and 4) . CALU3 has five copies of the topoisomerase IIa gene ( Figure  2b ) yet a 10-15-fold increase in expression over the other two cell lines. This suggests there may be further complexity in the regulation of the topoisomerase IIa gene at the transcriptional or post-transcriptional level.
The human genome has the potential to express a second topoisomerase II isozyme encoded by the topoisomerase II beta gene. There is still a paucity of data on the beta enzyme but since its cloning, recent chromosomal mapping and the generation of monoclonal antibodies against it, progress should now become more rapid (Jenkins et al., 1992; Negri et al., 1992) . It is known however that the beta enzyme is expressed, sensitive to inhibition by topoisomerase II interactive drugs and likely to be confined to the nucleolus (Jenkins et al., 1992; Drake et al., 1989; Negri et al., 1992) . Any model system used to study topoisomerase II inhibitors would therefore benefit from the analysis of both alpha and beta expression. In contrast to the alpha locus in CALU3, none of the three lung cancer cell lines used in this study have gross chromosomal changes at the beta locus (Keith et al., 1992) . By immunofluorescence there is little detectable difference in beta expression between the cell lines, with all lines expressing the beta isozyme in every cell (Figure 4) . The localisation of the beta product to the nucleoli confirms the data of Negri et al., 1992 and suggests a role for the beta product in ribosomal gene expression or organisation (Kim & Wang, 1989) . The data presented in Figure 4 on beta expression suggest that the beta product represents a target for inhibition and may be a target for topoisomerase II poisons in the absence of alpha isozyme expression.
In addition to the correlation between alpha gene amplification in CALU3 and high levels of alpha expression, biochemical assays for topoisomerase II activity confirmed a concomitant elevated level of activity which could be inhibited by etoposide (Figures 4 and 5) . Taken together, the Western blot analysis, immunofluorescence studies and the enzyme activity assays suggest that the sensitivity of CALU3 to topoisomerase inhibitors (Merry et al., 1987) importance to tumours where topoisomerase II alpha gene amplification has occurred, as these cases may benefit preferentially from treatment with topoisomerase II inhibitors. We have previously shown that the region of amplification found in primary breast tumours encompasses at least three loci including ERBB2, RARa and topoisomerase IIa. The PKCa locus was found to be outside the region of amplification showing that the increased copy number of the three genes is due to amplification rather than aneuploidy (Keith et al., 1993) . We have also previously shown that the lung adenocarcinoma cell line, CALU3, has co-amplification ERBB2 and topoisomerase IIa (Keith et al., 1992) . As part of our efforts to characterise similarities between the genetic events found around the topoisomerase IIa locus in breast cancer biopsies and the CALU3 cell line, we have shown that the RARa locus is also amplified in CALU3 (Figure 1) . By Southern analysis, topoisomerase Ila and RARa are amplified around 4-fold. The finding that the locus for PKCoa is not within the amplicon, is again consistent with the observations in breast cancer (Keith et al., 1992) and demonstrates that the increased copy number of ERBB2, RARa and topoisomerase IIa in CALU3 is not due to aneuploidy. The RARx receptor regulates normal cellular proliferation and differentiation through activation by retinoids, (Bollag & Holdener, 1992) and can, when expressed as a fusion protein in acute promyelocytic leukaemia act as an oncogene. (Clarkson, 1991) . Gebert et al. (1991) have shown the RARa gene to be expressed at high levels in CALU3 and so CALU3 may be a suitable model to study retinoids in cancer therapy, (Bollag & Holdener, 1992) .
The finding that topoisomerase II alpha can be amplified and expressed in adenocarcinomas opens the question as to whether there is intra-tumour heterogeneity in topoisomerase Ila gene amplification and its consequences for the sensitivity of subpopulations within the tumour to cytotoxic agents. Fluorescence in situ hybridisation is an ideal approach to study this heterogeneity. Indeed, it has recently been shown by FISH that in breast cancer biopsies there is considerable intra-tumour variation in ERBB2 copy number (Kallioniemi et al., 1992) . Our demonstration that amplification of topoisomerase II alpha can be studied by FISH (Figure 2) , opens up the possibility of examining the importance of topoisomerase gene amplification and allele imbalance at the single cell level.
